692 results match your criteria Brain Tumor Pathology[Journal]


Clinicopathological characteristics of circumscribed high-grade astrocytomas with an unusual combination of BRAF V600E, ATRX, and CDKN2A/B alternations.

Brain Tumor Pathol 2019 Apr 10. Epub 2019 Apr 10.

Department of Human Pathology, Gunma University Graduate School of Medicine, 3-39-22, Showa, Maebashi, 371-8511, Gunma, Japan.

We report four cases of high-grade astrocytoma with a BRAF V600E mutation, ATRX inactivation, and CDKN2A/B homozygous deletion. Children to young adults aged 3-46 presented with a well demarcated contrast-enhancing mass in the supratentorial area. Pathological examination revealed packed growth of short spindle to round polygonal cells including some pleomorphic cells. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10014-019-00344-z
Publisher Site
http://dx.doi.org/10.1007/s10014-019-00344-zDOI Listing
April 2019
2 Reads

Novel concept of the border niche: glioblastoma cells use oligodendrocytes progenitor cells (GAOs) and microglia to acquire stem cell-like features.

Brain Tumor Pathol 2019 Apr 9. Epub 2019 Apr 9.

Department of Neurosurgery, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, 252-0374, Japan.

Glioblastoma (GBM) is a major malignant brain tumor developing in adult brain white matter, characterized by rapid growth and invasion. GBM cells spread into the contralateral hemisphere, even during early tumor development. However, after complete resection of tumor mass, GBM commonly recurs around the tumor removal cavity, suggesting that a microenvironment at the tumor border provides chemo-radioresistance to GBM cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-019-00341-2DOI Listing

Preface.

Brain Tumor Pathol 2019 Apr 8. Epub 2019 Apr 8.

Nagoya University Hospital, 65, Tsurumai, Showa, Nagoya, Aichi, 466-8550, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-019-00342-1DOI Listing

Pilomyxoid astrocytomas: a short review.

Brain Tumor Pathol 2019 Apr 3. Epub 2019 Apr 3.

Neuropathology Division, Department of Pathology, UCSF School of Medicine, Moffitt, M551C, University of California, 505 Parnassus Avenue, Box 0102, San Francisco, CA, 94143, USA.

Pilomyxoid astrocytoma is a variant of pilocytic astrocytoma and the clinical, histological and molecular data point to a very close relationship as well as a more aggressive biological behavior for the former. WHO 2016 classification does not provide a specific grade for these neoplasms, but there is sufficient evidence in the literature that pilomyxoid astrocytoma has slightly worse prognosis than typical pilocytic astrocytoma. There is increasing evidence that in addition to the MAPK pathway alterations, pilomyxoid astrocytomas harbor genetic alterations that distinguish them from typical pilocytic astrocytoma. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10014-019-00343-0
Publisher Site
http://dx.doi.org/10.1007/s10014-019-00343-0DOI Listing
April 2019
4 Reads

Overview of DNA methylation in adult diffuse gliomas.

Brain Tumor Pathol 2019 Apr 1. Epub 2019 Apr 1.

Department of Neurosurgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan.

Adult diffuse gliomas form a heterogeneous group of tumors of the central nervous system that vary greatly in histology and prognosis. A significant advance during the last decade has been the identification of a set of genetic lesions that correlate well with histology and clinical outcome in diffuse gliomas. Most characteristic driver mutations consist of isocitrate dehydrogenase 1 (IDH1) and IDH2, and H3 histone family member 3A, which are strongly associated with DNA and histone methylation patterns. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-019-00339-wDOI Listing

Review of ependymomas: assessment of consensus in pathological diagnosis and correlations with genetic profiles and outcome.

Brain Tumor Pathol 2019 Mar 30. Epub 2019 Mar 30.

Department of Neuro-Oncology/Neurosurgery, Saitama Medical University International Medical Center, Saitama, Japan.

We focused on histological and immunohistochemical characteristics of ependymoma (EPN) with molecular profiles to develop more reproducible criteria of the diagnosis. Three expert neuropathologists reviewed the pathology of 130 samples from the Japan Pediatric Molecular Neuro-Oncology Group study. Confirmed cases were assessed for histology, surrogate markers, molecular subgrouping, and survival data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-019-00338-xDOI Listing
March 2019
2 Reads

Molecular genetics and therapeutic targets of pediatric low-grade gliomas.

Brain Tumor Pathol 2019 Mar 30. Epub 2019 Mar 30.

Department of Neurosurgery, Yokohama City University, 3-9 Fukuura, Kanazawa, Yokohama, 2360004, Japan.

Pediatric low-grade gliomas (PLGGs) have relatively favorable prognosis and some resectable PLGGs, such as cerebellar pilocytic astrocytoma, can be cured by surgery alone. However, many PLGG cases are unresectable and some of them undergo tumor progression. Therefore, a multidisciplinary approach is necessary to treat PLGG patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-019-00340-3DOI Listing
March 2019
3 Reads
2.281 Impact Factor

The emerging clinical potential of circulating extracellular vesicles for non-invasive glioma diagnosis and disease monitoring.

Brain Tumor Pathol 2019 Mar 11. Epub 2019 Mar 11.

Brainstorm Brain Cancer Research, Brain Tumour Research Laboratories, Brain and Mind Centre, University of Sydney, Camperdown, NSW, Australia.

Diffuse gliomas (grades II-IV) are amongst the most frequent and devastating primary brain tumours of adults. Currently, patients are monitored by clinical examination and radiographic imaging, which can be challenging to interpret and insensitive to early signs of treatment failure and tumour relapse. While brain biopsy and histologic analysis can evaluate disease progression, serial biopsies are invasive and impractical given the cumulative surgical risk, and may not capture the complete molecular landscape of an evolving tumour. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10014-019-00335-0
Publisher Site
http://dx.doi.org/10.1007/s10014-019-00335-0DOI Listing
March 2019
2 Reads

Pathologic and molecular aspects of anaplasia in circumscribed gliomas and glioneuronal tumors.

Brain Tumor Pathol 2019 Mar 11. Epub 2019 Mar 11.

Division of Neuropathology, Department of Pathology, Johns Hopkins University School of Medicine, Sheikh Zayed Tower, Room M2101, 1800 Orleans Street, Baltimore, MD, 21231, USA.

Many breakthroughs have been made in the past decade regarding our knowledge of the biological basis of the diffuse gliomas, the most common primary central nervous system (CNS) tumors. These tumors as a group are aggressive, associated with high mortality, and have a predilection for adults. However, a subset of CNS glial and glioneuronal tumors are characterized by a more circumscribed pattern of growth and occur more commonly in children and young adults. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-019-00336-zDOI Listing

Practical procedures for the integrated diagnosis of astrocytic and oligodendroglial tumors.

Brain Tumor Pathol 2019 Mar 7. Epub 2019 Mar 7.

Genomics Unit, Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan.

The publication of the 2016 World Health Organization Classification of Tumors of the Central Nervous System (2016 WHO CNS) represented a major change in the classification of brain tumors. However, many pathologists in Japan cannot diagnose astrocytic or oligodendroglial tumors according to the 2016 WHO CNS due to financial or technical problems. Therefore, the Japan Society of Brain Tumor Pathology established a committee for molecular diagnosis to facilitate the integrated diagnosis of astrocytic and oligodendroglial tumors in Japan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-019-00337-yDOI Listing

Next-generation whole exome sequencing of glioblastoma with a primitive neuronal component.

Brain Tumor Pathol 2019 Feb 4. Epub 2019 Feb 4.

Department of Pathology and Laboratory Medicine, North Shore University Hospital and Long Island Jewish Medical Center, Lake Success, 11042, NY, USA.

Glioblastoma with a primitive neuronal component (GBM-PN) was renamed from glioblastoma with primitive neuroectodermal tumor-like component (GBM-PNET) in the new WHO classification of tumors of the central nervous system in 2016. GBM-PN is a rare variant of glioblastoma. There were not so many publications on the investigation of GBM-PN. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10014-019-00334-1
Publisher Site
http://dx.doi.org/10.1007/s10014-019-00334-1DOI Listing
February 2019
6 Reads

A rapidly fatal intracranial anaplastic hemangiopericytoma with de-novo dedifferentiation: emphasis on diagnostic recognition, molecular confirmation and discussion on treatment dilemma.

Brain Tumor Pathol 2019 Jan 2;36(1):20-26. Epub 2019 Jan 2.

Department of Pathology, National University Health System, 5 Lower Kent Ridge Road, 119074, Singapore, Singapore.

Solitary fibrous tumors/ hemangiopericytomas (SFT/HPC) are mesenchymal tumors that share a common genetic aberration and very rarely undergo dedifferentiation. We report a unique case of an intracranial anaplastic SFT/HPC with de-novo dedifferentiation, which pursued a rapidly fatal clinical course in a 41-year-old lady. The dedifferentiated component comprised a focal area of glandular formation with epithelial immunophenotype acquisition. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-018-0333-0DOI Listing
January 2019
1 Read

Immunohistochemical detection of ALK protein identifies APC mutated medulloblastoma and differentiates the WNT-activated medulloblastoma from other types of posterior fossa childhood tumors.

Brain Tumor Pathol 2019 Jan 6;36(1):1-6. Epub 2018 Dec 6.

Department of Experimental and Clinical Pathology, Mossakowski Medical Research Centre, Polish Academy of Sciences, A. Pawińskiego 5 Street, 02-106, Warsaw, Poland.

Expression of the ALK gene strongly correlates with the WNT-activated medulloblastomas, which are routinely identified by detection of CTNNB1 mutation. However, some tumors have mutations in other than CTNNB1 genes. Therefore, we investigated if ALK expression may identify WNT-activated tumors without CTNNB1 mutation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-018-0331-2DOI Listing
January 2019
2 Reads

The clinicopathological analysis of receptor tyrosine kinases in meningiomas: the expression of VEGFR-2 in meningioma was associated with a higher WHO grade and shorter progression-free survival.

Brain Tumor Pathol 2019 Jan 5;36(1):7-13. Epub 2018 Dec 5.

Department of Pathology and Laboratory Medicine, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Ishikawa, 920-0293, Japan.

WHO grade II/III meningiomas recur frequently and there is currently no established molecular target therapy for meningioma. No previous studies have revealed the association between receptor tyrosine kinases (RTKs) and the recurrence of meningiomas. This study aims to elucidate the association between RTKs and the clinicopathological characteristics and recurrence of meningioma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-018-0332-1DOI Listing
January 2019
1 Read

Identification of a novel KLC1-ROS1 fusion in a case of pediatric low-grade localized glioma.

Brain Tumor Pathol 2019 Jan 22;36(1):14-19. Epub 2018 Oct 22.

Division of Brain Tumor Translational Research, National Cancer Center Research Institute, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

The proto-oncogene tyrosine-protein kinase ROS1 (ROS1) is a tyrosine kinase that is closely related to anaplastic lymphoma kinase receptor (ALK). We describe a novel KLC1-ROS1 fusion identified in a case of pediatric low-grade glioma. This was detected by RNA sequencing and confirmed by reverse-transcription PCR and fluorescent in situ hybridization. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10014-018-0330-3
Publisher Site
http://dx.doi.org/10.1007/s10014-018-0330-3DOI Listing
January 2019
12 Reads

Molecular profiling of different glioma specimens from an Ollier disease patient suggests a multifocal disease process in the setting of IDH mosaicism.

Brain Tumor Pathol 2018 Oct 29;35(4):202-208. Epub 2018 Aug 29.

Department of Pathology, Duke University Medical Center 3712, Davison Building, Durham, NC, 27710, USA.

Ollier disease (OD) and Maffucci syndrome are rare conditions due to a post-zygotic somatic mutation that results in mosaicism. In addition to enchondromas and hemangiomas, some of these patients also develop other unrelated tumors, such as gliomas, that harbor IDH mutations, suggesting that an IDH mutation is a common genetic event in the tumorigenesis in this group of patients. We illustrate an interesting case of multifocal IDH-mutant astrocytomas in an OD patient with 8 years of follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-018-0327-yDOI Listing
October 2018
2 Reads

NRAS mutated diffuse leptomeningeal melanomatosis in an adult patient with a brief review of the so-called "forme fruste" of neurocutaneous melanosis.

Brain Tumor Pathol 2018 Oct 25;35(4):217-223. Epub 2018 Aug 25.

Pathology Unit, Department of Pathology and Diagnostics, University and Hospital Trust of Verona, Verona, Italy.

Primary melanocytic tumors of central nervous system represent rare tumors arising from melanocytes of the leptomeninges. These neoplasms include focal forms like melanocytoma and primary malignant melanoma and diffuse forms like leptomeningeal melanocytosis and primary leptomeningeal melanomatosis. The clinical diagnosis remains challenging, with clinical and radiologic features overlapping with other more common diseases. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10014-018-0328-x
Publisher Site
http://dx.doi.org/10.1007/s10014-018-0328-xDOI Listing
October 2018
12 Reads

Anaplastic changes of diffuse leptomeningeal glioneuronal tumor with polar spongioblastoma pattern.

Brain Tumor Pathol 2018 Oct 26;35(4):209-216. Epub 2018 Jul 26.

Department of Neurosurgery, Hamamatsu University School of Medicine, 1-20-1, Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan.

Diffuse leptomeningeal glioneuronal tumor (DLGNT) is a rare glioneuronal neoplasm with oligodendroglioma-like cells confined in the subarachnoid spaces. A great majority of DLGNT are histologically low grade. However, some tumors show features of anaplasia with increased mitotic and proliferative activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-018-0326-zDOI Listing
October 2018
8 Reads

Paediatric diffuse leptomeningeal tumor with glial and neuronal differentiation harbouring chromosome 1p/19q co-deletion and H3.3 K27M mutation: unusual molecular profile and its therapeutic implications.

Brain Tumor Pathol 2018 Jul 20;35(3):186-191. Epub 2018 Jul 20.

Department of Pathology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.

Diffuse leptomeningeal glioneuronal tumor (DL-GNT) is a newly introduced tumor entity of uncertain prognosis characterised by a primary diffuse leptomeningeal growth pattern, oligodendroglial-like morphology and dual glial/neuronal differentiation. Predominantly occurring in children, these tumors present as chronic meningitis and mimic infectious/inflammatory diseases. They are surgically challenging tumors with a high incidence of delayed morbidity and mortality despite low-grade histology. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10014-018-0325-0
Publisher Site
http://dx.doi.org/10.1007/s10014-018-0325-0DOI Listing
July 2018
14 Reads

A surgical strategy for lower grade gliomas using intraoperative molecular diagnosis.

Brain Tumor Pathol 2018 Jul 6;35(3):159-167. Epub 2018 Jul 6.

Department of Neurosurgery, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.

Lower grade gliomas are both treated and diagnosed via surgical resection. Maximum tumor resection is currently the standard of care; however, this risks the loss of brain function. Glioma can be genetically subdivided into three different types, based on isocitrate dehydrogenase (IDH) mutation status and the presence of 1p/19q codeletion, which have radically different prognoses and responses to adjuvant therapies. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10014-018-0324-1
Publisher Site
http://dx.doi.org/10.1007/s10014-018-0324-1DOI Listing
July 2018
36 Reads

Importance and accuracy of intraoperative frozen section diagnosis of the resection margin for effective carmustine wafer implantation.

Brain Tumor Pathol 2018 Jul 14;35(3):131-140. Epub 2018 Jun 14.

Department of Neurosurgery, Hirosaki University Graduate School of Medicine, Zaifu-cho 5, Hirosaki, Aomori, 036-8562, Japan.

For effective implantation of carmustine (BCNU) wafers, it is important to determine the order of priority with reference to the intraoperative frozen section diagnosis of the resection margin (IOFM). The accuracy of IOFM and patterns of tumor recurrence with implantation of BCNU wafers were studied retrospectively. Forty-six cases of newly diagnosed malignant glioma were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-018-0320-5DOI Listing

Stromal cells of hemangioblastomas exhibit mesenchymal stem cell-derived vascular progenitor cell properties.

Brain Tumor Pathol 2018 Oct 23;35(4):193-201. Epub 2018 Jun 23.

Department of Neurosurgery, Kyoto University Graduate School of Medicine, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.

Hemangioblastoma is composed of neoplastic stromal cells and a prominent capillary network. To date, the identity of stromal cells remains unclear. Mesenchymal stem cells can give rise to committed vascular progenitor cells, and ephrin-B2/EphB4 and Notch signaling have crucial roles in these steps. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-018-0323-2DOI Listing
October 2018
1 Read

Impact of PCR-based molecular analysis in daily diagnosis for the patient with gliomas.

Brain Tumor Pathol 2018 Jul 21;35(3):141-147. Epub 2018 Jun 21.

Department of Neurosurgery, Faculty of Medicine, University of Miyazaki, Miyazaki, 889-1692, Japan.

The WHO2016 CNS update requires a combined histological and molecular assessment. To assess the major aberrations such as co-deletion of complete chromosome arms 1p and 19q (Co-del), isocitrate dehydrogenase and histone H3 mutations, direct sequencing, multiplex ligation-dependent probe amplification and/or FISH are methods considered to be "golden standard" in the community. However, these methods are expensive and complicated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-018-0322-3DOI Listing
July 2018
20 Reads

Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas.

Brain Tumor Pathol 2018 Jul 19;35(3):148-158. Epub 2018 Jun 19.

Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

The radiological features of lower-grade gliomas (LGGs) classified according to isocitrate dehydrogenase (IDH) mutations and codeletion of chromosomal arms 1p and 19q (1p/19q codeletion) remain unclear. We aimed to systematically characterize the radiological features of molecularly classified LGGs using IDH and 1p/19q codeletion statuses. One hundred and one LGGs were re-classified into 36 tumors with IDH mutations (IDH-Mut), 35 tumors with IDH-Mut and 1p/19q codeletion (IDH-Mut/Codel), and 30 tumors with wildtype IDH (IDH-Wt). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-018-0321-4DOI Listing
July 2018
50 Reads

A case of epidural glioblastoma metastasis presenting with a cervical myelopathy, torticollis, and L'hermitte's phenomenon.

Brain Tumor Pathol 2018 Jul 9;35(3):181-185. Epub 2018 May 9.

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA.

Extraneural glioblastoma metastases are exceedingly rare, though previously described in the literature. Activating mutations in the BRAF kinase gene (V600E) are present in a minority of glioblastoma patients. Here, we describe a case of systemic metastases of a clonal subpopulation of BRAF V600E mutated glioblastoma in a patient previously treated with surgery, radiation, temozolomide and bevacizumab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-018-0319-yDOI Listing
July 2018
18 Reads

The 2017 WHO classification of pituitary adenoma: overview and comments.

Brain Tumor Pathol 2018 Apr 23;35(2):51-56. Epub 2018 Apr 23.

Department of Hypothalamic and Pituitary Surgery, Toranomon Hospital, Tokyo, Japan.

The fourth edition of the World Health Organization classification of endocrine tumors has been recently published. There are two critical changes to the classification for pituitary adenomas in this edition. One is that the term "atypical adenoma," which was characterized based on highly proliferative properties to predict adenomas that carry a poor prognosis, was completely eliminated due to the lack of definitive evidence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-018-0314-3DOI Listing
April 2018
9 Reads

Histopathological features to define atypical meningioma: What does really matter for prognosis?

Brain Tumor Pathol 2018 Jul 18;35(3):168-180. Epub 2018 Apr 18.

Dipartimento di Scienze biomediche, odontoiatriche e delle immagini morfologiche e funzionali, University of Messina, Messina, Italy.

Atypical meningiomas are diagnosed in the presence of: (1) three or more of the following minor atypical criteria: increased cellularity, small cells with a high nuclear/cytoplasmic ratio, prominent nucleoli, sheeting, and foci of spontaneous or geographic necrosis; (2) mitotic count ≥ 4 mitoses per 10 HPF (high mitotic index); (3) brain invasion. The 5-year disease-free survival (DFS) is around 50%. Due to their heterogeneous behavior, the post-surgical treatment of atypical meningiomas is controversial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-018-0318-zDOI Listing
July 2018
1 Read

Rapid detection of mutation in isocitrate dehydrogenase 1 and 2 genes using mass spectrometry.

Brain Tumor Pathol 2018 Apr 18;35(2):90-96. Epub 2018 Apr 18.

Department of Neurosurgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.

The 2016 World Health Organization classification of tumors of the central nervous system was recently revised. Mutations in the isocitrate dehydrogenase 1 (IDH1) and IDH2 genes and chromosome 1p/19q codeletion are especially important for both the integrated diagnosis and the determination of surgical strategy. To establish a method for intraoperative molecular diagnosis, a simple, rapid method was developed for the measurement of 2-hydroxyglutarate (2-HG), a specific oncometabolite formed in the presence of IDH gene mutation, using liquid chromatography/electrospray ionization tandem mass spectrometry (LC/ESI-MS/MS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-018-0317-0DOI Listing
April 2018
7 Reads

Three case reports of radiation-induced glioblastoma after complete remission of acute lymphoblastic leukemia.

Brain Tumor Pathol 2018 Apr 17;35(2):114-122. Epub 2018 Apr 17.

Department of Neurosurgery, Graduate School of Medicine, Tohoku University, 1-1 Seiryo-cho, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.

Radiation therapy is sometimes performed to control intracranial acute lymphoblastic leukemia (ALL), but may lead to radiation-induced malignant glioma. The clinical, radiological, histological, and molecular findings are described of three cases of radiation-induced glioblastoma after the treatment for ALL. They received radiation therapy at age 6-8 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-018-0316-1DOI Listing
April 2018
6 Reads

A feast of reviews about brain and pituitary tumor pathology.

Authors:
David N Louis

Brain Tumor Pathol 2018 Apr;35(2):49-50

Massachusetts General Hospital and Harvard Medical School, Boston, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-018-0315-2DOI Listing
April 2018
3 Reads

Reclassification of 400 consecutive glioma cases based on the revised 2016WHO classification.

Brain Tumor Pathol 2018 Apr 22;35(2):81-89. Epub 2018 Mar 22.

Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, Fukuoka, 812-8582, Japan.

In this study, we reclassified 400 consecutive glioma cases including pediatric cases, using the revised 2016 WHO classification with samples collected from the Kyushu University Brain Tumor Bank. The IDH1/2, H3F3A, key genetic markers in the 2016 classification, were analyzed using high-resolution melting, with DNA extracted from frozen tissues. The 1p/19q codeletions were evaluated using a microsatellite-based loss of heterozygosity analysis, with 18 markers, to detect loss of the entire chromosome arm. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-018-0313-4DOI Listing
April 2018
2 Reads

Immunohistochemical ATRX expression is not a surrogate for 1p19q codeletion.

Brain Tumor Pathol 2018 Apr 17;35(2):106-113. Epub 2018 Mar 17.

Department of Neurosurgery, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan.

The IDH-mutant and 1p/19q co-deletion (1p19q codel) provides significant diagnostic and prognostic value in lower-grade gliomas. As ATRX mutation and 1p19q codel are mutually exclusive, ATRX immunohistochemistry (IHC) may substitute for 1p19q codel, but this has not been comprehensively examined. In the current study, we performed ATRX-IHC in 78 gliomas whose ATRX statuses were comprehensively determined by whole exome sequencing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-018-0312-5DOI Listing

Welcoming the new WHO classification of pituitary tumors 2017: revolution in TTF-1-positive posterior pituitary tumors.

Authors:
Makoto Shibuya

Brain Tumor Pathol 2018 Apr 2;35(2):62-70. Epub 2018 Mar 2.

Central Clinical Laboratory, Hachioji Medical Center, Tokyo Medical University, 1163 Tatemachi, Hachioji City, Tokyo, 193-0998, Japan.

The fourth edition of the World Health Organization classification of endocrine tumors (EN-WHO2017) was released in 2017. In this new edition, changes in the classification of non-neuroendocrine tumors are proposed particularly in tumors arising in the posterior pituitary. These tumors are a distinct group of low-grade neoplasms of the sellar region that express thyroid transcription factor-1, and include pituicytoma, granular cell tumor of the sellar region, spindle cell oncocytoma, and sellar ependymoma. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10014-018-0311-6
Publisher Site
http://dx.doi.org/10.1007/s10014-018-0311-6DOI Listing
April 2018
9 Reads

Whole-exome sequencing of a meningeal melanocytic tumour reveals activating CYSLTR2 and EIF1AX hotspot mutations and similarities to uveal melanoma.

Brain Tumor Pathol 2018 04 23;35(2):127-130. Epub 2018 Feb 23.

Department of Neurosurgery, Radboud University Medical Center, P.O. Box 9101, IPC 633, 6500 HB, Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-018-0308-1DOI Listing
April 2018
2 Reads

Clinical significance of the 2016 WHO classification in Japanese patients with gliomas.

Brain Tumor Pathol 2018 Apr 22;35(2):71-80. Epub 2018 Feb 22.

Division of Surgical Pathology, Chiba Cancer Center, Chiba, Japan.

In this study, we retrospectively compared the prognostic value of the 2016 WHO classification with the former classification in 387 patients with glioma treated at our institution. According to the new classification, diagnoses included oligodendroglioma with isocitrate dehydrogenase (IDH) mutation and 1p/19q co-deletion (5.4%), anaplastic oligodendroglioma with IDH mutation and 1p/19q co-deletion (3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-018-0309-0DOI Listing
April 2018
5 Reads

A novel high-sensitivity assay to detect a small fraction of mutant IDH1 using droplet digital PCR.

Brain Tumor Pathol 2018 Apr 19;35(2):97-105. Epub 2018 Feb 19.

Department of Neurosurgery, Nagoya University, Nagoya, Japan.

Detection of mutations in the isocitrate dehydrogenase 1 (IDH1) gene is useful for accurate diagnosis of lower grade gliomas, as described in the 2016 World Health Organization classification of tumors of the central nervous system. Conventional analysis tools, including Sanger DNA sequencing and immunohistochemistry, might fail to detect a small fraction of mutant IDH1 owing to their limited sensitivity. Considering that lower grade gliomas are infiltrative in nature, a highly sensitive detection assay for IDH1 mutation is required for their accurate diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-018-0310-7DOI Listing
April 2018
8 Reads

Delayed leptomeningeal metastasis of an adult anaplastic pilocytic astrocytoma.

Brain Tumor Pathol 2018 04 13;35(2):123-126. Epub 2018 Jan 13.

Department of Neurological Surgery, Loyola University Stritch School of Medicine, 2160 South First Avenue, Maywood, IL, 60153, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-017-0306-8DOI Listing
April 2018
2 Reads

New WHO classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors.

Brain Tumor Pathol 2018 Apr 9;35(2):57-61. Epub 2018 Jan 9.

Department of Pathology, Toranomon Hospital, Tokyo, Japan.

WHO classification of pituitary adenomas was revised in 2017. The two major and significant changes are discussed. (1) The new classification focuses on adenohypophysial-cell lineage for the designation of adenomas, and thus, assessment of pituitary transcription factors is recommended. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-017-0307-7DOI Listing
April 2018
12 Reads

A case report of adult cerebellar high-grade glioma with H3.1 K27M mutation: a rare example of an H3 K27M mutant cerebellar tumor.

Brain Tumor Pathol 2018 Jan 20;35(1):29-35. Epub 2017 Dec 20.

Department of Neurosurgery, Saiseikai Yokohamashi Tobu Hospital, 3-6-1 Shimosueyoshi, Tsurumi-ku, Yokohama, Kanagawa, 230-0012, Japan.

Diffuse midline glioma, H3 K27M mutant, is newly recognized as a distinct category, which usually arises in the brain stem, thalamus or spinal cord of children, and young adults. The oncogenic H3 K27M mutation involves H3.3 (encoded by H3F3A) or H3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-017-0305-9DOI Listing
January 2018
5 Reads

Research of differential expression of sIL1RAP in low-grade gliomas between children and adults.

Brain Tumor Pathol 2018 Jan 13;35(1):19-28. Epub 2017 Dec 13.

Department of Pediatric Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China.

Glioma is the most common intracranial malignant tumor. Low-grade gliomas (LGG) occupy almost 80% in all of the gliomas. The prognosis of LGG in children is much better than in adult, however, the molecular mechanism is still unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-017-0304-xDOI Listing
January 2018
2 Reads

Enchondromatosis-associated oligodendroglioma: case report and literature review.

Brain Tumor Pathol 2018 Jan 9;35(1):36-40. Epub 2017 Dec 9.

Department of Neurosurgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.

Enchondromatosis is a rare skeletal disorder characterized by the development of multiple enchondromas, which can also manifest non-cartilage tumors including gliomas. Here, we describe a genetic analysis of a low-grade glioma that developed in an enchondromatosis case. A 32-year-old man with a long history of enchondromatosis developed a left frontal tumor. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10014-017-0303-y
Publisher Site
http://dx.doi.org/10.1007/s10014-017-0303-yDOI Listing
January 2018
9 Reads

Glioblastoma in neurofibromatosis 1 patients without IDH1, BRAF V600E, and TERT promoter mutations.

Brain Tumor Pathol 2018 Jan 14;35(1):10-18. Epub 2017 Nov 14.

Department of Neurosurgery, Tohoku University School of Medicine, Sendai, Japan.

Pilocytic astrocytomas and low-grade gliomas are more common compared with glioblastomas in patients with neurofibromatosis 1 (NF1). A recent genome-wide analysis has shown frequent NF1 gene alterations in the mesenchymal subtype of a glioblastoma; however, little is known about clinicopathological features of glioblastomas in NF1 patients (NF1 glioblastomas). We analyzed four NF1 glioblastomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-017-0302-zDOI Listing
January 2018
19 Reads

RELA fusion-positive anaplastic ependymoma: molecular characterization and advanced MR imaging.

Brain Tumor Pathol 2018 01 11;35(1):41-45. Epub 2017 Oct 11.

Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima-City, Hiroshima, 734-8551, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-017-0301-0DOI Listing
January 2018
6 Reads

Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas.

Brain Tumor Pathol 2018 Jan 8;35(1):1-9. Epub 2017 Sep 8.

Department of Neurosurgery, University of California, Los Angeles, 300 Stein Plaza, Los Angeles, CA, 90095, USA.

Epithelial membrane protein-2 (EMP2) expression is noted in many human cancers. We evaluated EMP2 as a biomarker in gliomas. A large tissue microarray of lower grade glioma (WHO grades II-III, n = 19 patients) and glioblastoma (GBM) (WHO grade IV, n = 50 patients) was stained for EMP2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-017-0300-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6118858PMC
January 2018
20 Reads

Updated 2016 WHO classification of tumors of the CNS: turning the corner where molecule meets pathology.

Authors:
Takashi Komori

Brain Tumor Pathol 2017 Oct;34(4):139-140

Department of Laboratory Medicine and Pathology (Neuropathology), Tokyo Metropolitan Neurological Hospital, 2-6-1 Musashidai, Fuchu, Tokyo, 183-0042, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-017-0299-3DOI Listing
October 2017

Diencephalic pediatric low-grade glioma harboring the BRAF V600E mutation presenting with various morphologies in sequential biopsy specimens.

Brain Tumor Pathol 2017 Oct 23;34(4):165-171. Epub 2017 Aug 23.

Department of Neurosurgery, Hokkaido University School of Medicine, North 15 West 7, Kita-ku, Sapporo, 060-8638, Japan.

A 5-year-old boy underwent biopsy of an intra-axial calcified tumor in the hypothalamus, which was incidentally found. Based on the presence of ganglion-like cells combined with glial cell element, the pathological diagnosis was ganglioglioma. Because the tumor grew gradually in size over the next 2 years, he underwent chemotherapy with temozolomide. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-017-0298-4DOI Listing
October 2017
33 Reads

Encouraging option of multi-staged gross total resection for a C11orf-RelA fusion-positive supratentorial anaplastic ependymoma.

Brain Tumor Pathol 2017 Oct 22;34(4):160-164. Epub 2017 Aug 22.

Department of Neurosurgery, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.

Ependymomas are primary neuroepithelial malignancies that mainly occur during childhood, and arise from ependymal cells along the ventricular systems of the CNS. Recently, it was elucidated that two-thirds of supratentorial (ST) ependymomas harbor oncogenic fusions of RELA, whose protein product is the principal effector of canonical NF-κB signaling. RELA fusion proteins activate signaling for tumor proliferation and malignant progression, resulting in poorer prognoses in these patients compared to those in patients with other ST ependymomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-017-0297-5DOI Listing
October 2017
79 Reads

Downregulation of SMARCB1/INI1 expression in pediatric chordomas correlates with upregulation of miR-671-5p and miR-193a-5p expressions.

Brain Tumor Pathol 2017 Oct 20;34(4):155-159. Epub 2017 Aug 20.

Department of Pathology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.

Loss of SMARCB1/INI1 expression is considered to be a hallmark for childhood chordomas (CCs). Although mutation/loss of 22q has strongly established the loss of SMARCB1/INI1 in cancers, the cause in CCs remains elusive. Recent studies suggest role of miRNAs in regulation of SMARCB1/INI1 expressions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-017-0295-7DOI Listing
October 2017
37 Reads

Modified rapid immunohistochemical staining for intraoperative diagnosis of malignant brain tumors.

Brain Tumor Pathol 2017 Oct 19;34(4):141-148. Epub 2017 Aug 19.

Faculty of Advanced Techno-Surgery, Tokyo Women's Medical University, 8-1 Kawada-Cho, Shinjuku-Ku, Tokyo, 162-8666, Japan.

Rapid immunohistochemistry (R-IHC) has been developing mainly as a support technique in the rapid diagnosis of central nervous system tumors; however, there have been problems regarding instability in specimen preparation and immunostaining. To overcome the weakness of this technology, the instability of immunostaining, we developed a modified R-IHC. This was achieved by switching to 4% paraformaldehyde as the fixative solution and utilizing a commercially available Polymer Refine Detection Kit, as a high-sensitivity kit, in place of the secondary antibodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10014-017-0293-9DOI Listing
October 2017
5 Reads